NASDAQ:NVCNNeovasc Stock Price, Forecast & News

Neovasc's stock was trading at $2.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVCN shares have increased by 11.8% and is now trading at $2.47. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neovasc.

Neovasc is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Neovasc.

Neovasc Inc (NASDAQ:NVCN) posted its quarterly earnings results on Thursday, May, 7th. The medical equipment provider reported ($0.38) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.55) by $0.17. The medical equipment provider had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.60 million. View Neovasc's earnings history.

Neovasc's stock reverse split on the morning of Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

Neovasc updated its second quarter 2020 IntraDay earnings guidance on Monday, July, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $295K - 295K.

3 brokers have issued twelve-month target prices for Neovasc's shares. Their forecasts range from $3.00 to $15.00. On average, they anticipate Neovasc's share price to reach $7.67 in the next twelve months. This suggests a possible upside of 210.4% from the stock's current price. View analysts' price targets for Neovasc.

Media headlines about NVCN stock have trended negative this week, InfoTrie reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neovasc earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Neovasc.

Neovasc saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 210,600 shares, a decline of 14.1% from the May 31st total of 245,300 shares. Based on an average trading volume of 216,500 shares, the short-interest ratio is presently 1.0 days. Approximately 1.9% of the shares of the stock are sold short. View Neovasc's Current Options Chain.

Some companies that are related to Neovasc include Spectral Medical (EDTXF), Venus Concept (VERO), PAVmed (PAVM), SANUWAVE Health (SNWV), Nephros (NEPH), AIT Therapeutics (AITB), Pro-Dex (PDEX), Nephros (NEPHD), BRAINSWAY LTD/S (BWAY), Titan Medical (TMDI), Sensus Healthcare (SRTS), STRATA Skin Sciences (SSKN), Motus GI (MOTS), Neuronetics (STIM) and Apollo Endosurgery (APEN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Amicus Therapeutics (FOLD), Protalix Biotherapeutics (PLX), 22nd Century Group (XXII), Immune Pharmaceuticals (IMNP), Advanced Micro Devices (AMD) and Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCN stock can currently be purchased for approximately $2.47.

Neovasc has a market capitalization of $27.50 million and generates $2.09 million in revenue each year. The medical equipment provider earns $-35,130,000.00 in net income (profit) each year or ($5.05) on an earnings per share basis. Neovasc employs 98 workers across the globe.

The official website for Neovasc is www.neovasc.com.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-248-4138 or via email at [email protected]